Insignificant systemic exposure. The substance is not metabolised and does not interact with CYPs.

Antiviral neuramidase inhibitor used (inhalation 2x5 mg twice daily for 5 days) in symptomatic influenza A and B in adults and children > 12 years. The dose is deposited (about 80%) in oropharynx. Eliminated from there to the gastrointestinal tract with bioavailability of only 2 %. No metabolism takes place. No interaction with the metabolism of other drugs is observed.